1/41
Looks like no tags are added yet.
What are some statistics for Alzheimer’s Disease?
the 6th leading cause of death in the US
5.3 million Americans currently have AD
50% of people age 85 and older have AD
AD is not a normal part of aging
What is the histopathology of AD?
amyloid plaques
neurofibrillary tangles
What are the characteristics of amyloid plaques?
accumulate between neurons
insoluble B-amyloid
What are the characteristics neurofibrillary tangles?
accumulate in neurons
abnormal Tau
How does β-amyloid immunostaining detect plaques?
An anti-Aβ antibody binds Aβ, and a reaction makes a brown color there
How does silver impregnation differ from Aβ immunostaining?
It is less specific: it stains plaques plus neurites and tangles
In silver-stained neuritic plaques, what surrounds the dense amyloid core?
A halo of swollen, dystrophic neurites
Where are amyloid plaques located relative to neurons?
Extracellular, between neurons
What are the characteristics of amyloid beta?
a peptide of 39-43 amino acids
the main constituent of amyloid plaques, plaques in Lewy body dementia, and cerebral amyloid angiopathy
What are the most common isoforms of amyloid beta?
AB40 (more common) - produced in the ER
AB42 (more fibrillogenic) - produced in the TGN
How is amyloid beta formed?
formed after sequential cleavage of the amyloid precursor protein (APP) by B-secretase and y-secretase
What does AD dementia correlate strongly with?
soluble AB abundance
decreased spine density
What does AD dementia correlate poorly with?
amyloid plaques
What happens in a high level of AB (1-42)?
does not induce plaques in vivo
What does soluble AB do?
impairs synapse physiology in the absence of amyloid plaques
What is true of amyloid plaques in synapse physiology and neurotoxicity?
synapse loss around the amyloid plaque cores in AD mice
fibrillary amyloid aggregates cause neurotoxicity
What is true of AB in synapse physiology and neurotoxicity?
AB forms multiple oligomers
soluble AB oligomers kill neurons at nM concentration
synthetic or cell-derived soluble AB oligomers potently inhibit hippocampal LTP, but induces LTD before toxicity
AB causes synapses and spine loss even without plaques
AB toxicity via modulation of NMDAR, mGluR, and nAChR
What was the main gap in the field that Shankar et al. 2008 addressed?
The pathogenic Aβ species in the human brain had not been identified, and Aβ from human AD brain had not been shown to directly cause AD's neurobiological deficits
State the central hypothesis of Shankar et al. 2008.
Soluble Aβ oligomers extracted directly from human AD cortex impair synaptic plasticity and memory, with dimers as the smallest synaptotoxic species.
What three fractions were brain homogenates separated into, and with what?
Soluble (TBS), membrane-associated (TBS + 1% Triton X-100), insoluble (5 M guanidine HCl)
Why fractionate at all, rather than just blot whole homogenate?
Different pools may differ in disease relevance; dementia correlates with soluble Aβ, so they needed to know which pool held what
What made the P-AD (pathological AD, no dementia) case so informative in Figure 1?
Aβ appeared in its insoluble but not its soluble fraction — plaques without dementia, and without soluble Aβ
What happened to LTP with AD TBS versus control TBS (Fig. 2b)?
AD TBS reduced LTP to ~111% of baseline; Veh and Con TBS gave ~153% and ~144%
What two controls showed the LTP inhibition was specifically due to Aβ from AD brain?
Immunodepletion with R1282 prevented it, and DLB/FTD extracts did not inhibit LTP
Why was a subthreshold LFS protocol (300 pulses at 1 Hz) used for the LTD experiment?
It is too weak to induce LTD alone, so any LTD reveals facilitation by AD TBS
Which receptor is required for AD TBS–facilitated LTD, and what is the evidence?
mGluR: MCPG and SIB1757 blocked it, but the NMDAR antagonist AP-V did not
How does the passive avoidance test measure memory?
Rodents prefer dark; a foot shock there means a long latency to re-enter indicates intact memory
At which post-training injection time did AD TBS impair recall, and what does that timing imply?
3 h only — matching the transcriptional regulation of synapse remodeling, so it disrupts consolidation
Why is dendritic spine density the right readout for structural damage in AD?
Decreased spine density is the strongest neuropathological correlate of dementia severity in AD
What was the spine density result, and which antagonist blocked it?
AD TBS-SEC caused a 47% decrease; CPP (NMDAR) blocked it, MCPG (mGluR) did not
What is the double dissociation between the LTD and spine density experiments?
mGluRs are required for LTD facilitation; NMDARs are required for spine loss
In nondenaturing SEC of AD TBS, which fraction inhibited LTP?
Fraction 8 (dimers, ~8–16 kDa); fractions 4 (void) and 10 (monomers) were inactive
Fraction 4 had the highest Aβ concentration but no activity. Why?
Its high-MW complexes are held together noncovalently and only dissociate into monomers and dimers when denatured in LDS-PAGE
What is the Aβ40-S26C experiment, and what does it prove?
A synthetic peptide engineered to dimerize on oxidation; oxidized dimer inhibited LTP ~20× more potently than WT, proving Aβ dimers alone are sufficient
Did insoluble amyloid cores alter LTP (Fig. 4)?
Intact cores in ACSF did not; formic acid extracts of those same cores did
How does Figure 4 resolve the poor correlation between plaque burden and dementia?
Plaques are relatively inert reservoirs of bioactive oligomers — they contain synaptotoxic dimers but don't readily release them
What is the single most important result of Shankar et al. 2008?
Soluble Aβ isolated directly from human AD brain is sufficient to produce AD-like synaptic and memory deficits in normal rodents
What is the second key result, about which Aβ species is responsible?
Dimers are the smallest synaptotoxic species; monomers and intact plaque cores are inactive
Why do the authors hedge on the receptor double dissociation as a "key result"?
They state these receptors are unlikely to be the sole effector targets of soluble Aβ oligomers
Does this paper fill the stated gap in the field?
Substantially yes — it identifies the pathogenic species and shows human-brain Aβ causes the deficits — but acute rodent assays don't fully model a decades-long disease
What is the overall significance of Shankar et al. 2008?
It identified soluble Aβ dimers from human AD brain as a synaptotoxic species sufficient to cause AD-like deficits, shifting the therapeutic target from plaques to soluble oligomers
Which future directions did the authors themselves raise?
Identify effector targets beyond mGluR/NMDAR; resolve why Aβ*56 wasn't detected in human extracts; determine the role of CSF dimers